{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:41:44Z","timestamp":1794476504792,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["25293108"],"award-info":[{"award-number":["25293108"]}]},{"name":"JSPS KAKENHI","award":["25461508"],"award-info":[{"award-number":["25461508"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.antiviral.2016.12.008","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T13:48:18Z","timestamp":1482587298000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor"],"prefix":"10.1016","volume":"139","author":[{"given":"Misako","family":"Yajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Daikoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiyasu","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.12.008_bib1","first-page":"254","article-title":"Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections","volume":"7","author":"Balfour","year":"1994","journal-title":"J.\u00a0Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2016.12.008_bib2","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1099\/vir.0.011221-0","article-title":"A\u00a0mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in\u00a0vitro and lower virulence in a murine infection model is related to the predicted helicase structure","volume":"90","author":"Biswas","year":"2009","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.12.008_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4155\/fmc.13.192","article-title":"Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections","volume":"6","author":"Biswas","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.antiviral.2016.12.008_bib4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.AOG.0000180779.35572.3a","article-title":"Genital herpes complicating pregnancy","volume":"106","author":"Brown","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.antiviral.2016.12.008_bib5","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2016.12.008_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2012.05.020","article-title":"Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir)","volume":"84","author":"Chono","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2016.12.008_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2012.12.006","article-title":"Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus","volume":"97","author":"Chono","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.12.008_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.12.008_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm0402-327","article-title":"New anti-HSV therapeutics target the helicase-primase complex","volume":"8","author":"Crumpacker","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.12.008_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.12.008_bib11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jdermsci.2016.02.006","article-title":"Subclinical generation of acyclovir-resistant herpes simplex virus with mutation of homopolymeric guanosine strings during acyclovir therapy","volume":"82","author":"Daikoku","year":"2016","journal-title":"J.\u00a0Dermatol. Sci."},{"issue":"Suppl.\u00a0A","key":"10.1016\/j.antiviral.2016.12.008_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/32.suppl_A.121","article-title":"Antivirals for the treatment of herpesvirus infections","volume":"32","author":"De Clercq","year":"1993","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2016.12.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy","volume":"147","author":"De Clercq","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.antiviral.2016.12.008_bib14","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1128\/JCM.39.12.4362-4369.2001","article-title":"Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR","volume":"39","author":"Griscelli","year":"2001","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2016.12.008_bib15","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1099\/vir.0.18880-0","article-title":"Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir","volume":"84","author":"Harris","year":"2003","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.antiviral.2016.12.008_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.antiviral.2011.11.015","article-title":"Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in\u00a0vitro and in\u00a0vivo","volume":"93","author":"Himaki","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.12.008_bib17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/095632020101200404","article-title":"Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2","volume":"12","author":"Honda","year":"2001","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2016.12.008_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cpt.3","article-title":"Helicase-primase as a target of new therapies for herpes simplex virus infections","volume":"97","author":"James","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2016.12.008_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.coviro.2014.06.003","article-title":"Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance","volume":"8","author":"James","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2016.12.008_bib20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/AAC.01803-12","article-title":"Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection","volume":"57","author":"Katsumata","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.008_bib21","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.3390\/molecules16097210","article-title":"Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a Guinea pig model of genital herpes","volume":"16","author":"Katsumata","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2016.12.008_bib22","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1128\/AAC.00133-12","article-title":"Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor","volume":"56","author":"Katsumata","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.12.008_bib23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.12.008_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-3565(24)29548-3","article-title":"Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in\u00a0vitro and in\u00a0vivo","volume":"297","author":"Kurokawa","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.antiviral.2016.12.008_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0166-3542(93)90094-Y","article-title":"Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in\u00a0vitro and their therapeutic efficacies for HSV-1 infection in mice","volume":"22","author":"Kurokawa","year":"1993","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.12.008_bib26","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2165\/00003495-200060060-00007","article-title":"Current recommendations for the treatment of genital herpes","volume":"60","author":"Leung","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2016.12.008_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1586\/14787210.1.2.283","article-title":"Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster","volume":"1","author":"Moomaw","year":"2003","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2016.12.008_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/515385","article-title":"Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group","volume":"178","author":"Reitano","year":"1998","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.12.008_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.07.010","article-title":"Inhibitory activity of oxyresveratrol on wild-type and drug-resistant varicella-zoster virus replication in\u00a0vitro","volume":"84","author":"Sasivimolphan","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.12.008_bib30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jis019","article-title":"ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study","volume":"205","author":"Tyring","year":"2012","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.12.008_bib31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/01.olq.0000204723.15765.91","article-title":"Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding","volume":"33","author":"Wald","year":"2006","journal-title":"Sex. Transm. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216304521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216304521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T17:32:46Z","timestamp":1749835966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216304521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":31,"alternative-id":["S0166354216304521"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.12.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}